Mojca J. L.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 1 Evaluation of Allo-RevCAR01-T-CD123 in CD123 Positive Hematologic Malignancies, Including Acute Myeloid Leukemia (AML)
- Phase III Randomized, Placebo-Controlled Study of Venetoclax with Induction and Consolidation Chemotherapy in Newly Diagnosed AML or MDS-EB2 Patients
- Phase 1/2a Open-Label Study of MP0533 in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Data & Insights
Has run more than one trial at 57 of 192 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of blood and lymphatic system cancers, with particular focus on both acute and chronic conditions.
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Acute Mixed-Phenotype Leukemia (AMPL)
The investigator has expertise in managing relapsed and refractory cases of these conditions.
Lymphoma Studies
The investigator focuses on treating aggressive and indolent forms of lymphoid malignancies.
- Diffuse Large B-cell Lymphoma (DLBCL)
- Small Lymphocytic Lymphoma (SLL)
Their work includes investigating novel therapeutic approaches for treatment-resistant lymphomas.
Chronic Leukemia
The investigator has developed expertise in managing chronic lymphoid disorders, particularly:
- Chronic Lymphocytic Leukemia (CLL)
Their work encompasses both initial treatment strategies and management of relapsed/refractory disease states.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.